Related Experiment Video

Updated: May 5, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

11.5K

Canagliflozin: a novel treatment option for type 2 diabetes

Eric Dietrich1, Jason Powell, James R Taylor

  • 1University of Florida College of Medicine, Department of Community Health and Family Medicine, Gainesville, FL, USA.

Drug Design, Development and Therapy
|November 29, 2013
PubMed

Insights

Canagliflozin, a new type 2 diabetes medication, lowers hemoglobin A1c, weight, and blood pressure by increasing glucose excretion. While effective, it carries risks of infections and hypoglycemia.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Type 2 diabetes management remains a significant clinical challenge.
  • Novel therapeutic agents are needed to improve glycemic control.
  • Canagliflozin represents a new class of antidiabetic drugs.

Purpose of the Study:

  • To review the efficacy and safety of canagliflozin.
  • To evaluate its mechanism of action in managing type 2 diabetes mellitus.
  • To assess its potential role in clinical practice.

Main Methods:

  • Review of existing literature on canagliflozin.
  • Analysis of clinical trial data regarding its effects on glycemic control and other parameters.
  • Assessment of adverse event profiles.

Main Results:

  • Canagliflozin reduces hemoglobin A1c by 0.37%-1.16%.
  • It also leads to reductions in body weight and systolic blood pressure.
  • The drug has a low risk of hypoglycemia but an increased risk of genitourinary infections.

Conclusions:

  • Canagliflozin offers a unique mechanism for type 2 diabetes management.
  • It provides glycemic control benefits alongside weight and blood pressure reduction.
  • Clinicians should consider potential adverse effects when prescribing canagliflozin.
Keywords:
SGLT2 inhibitorcanagliflozinoral hypoglycemictype 2 diabetes

More Related Videos

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes05:18

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

Published on: February 17, 2023

8.1K
Isolated Pancreatic Islet Treatment and Apoptosis Measurement09:36

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Published on: May 2, 2025

969

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
998
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.5K